Buchang Group
Buchang Pharma (????) provides pharmaceutical products, research, and sales in China.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 12 % | (2 %) | (5 %) | (11 %) | (17 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 20 % | 18 % | 16 % | 16 % | 14 % | 12 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 14 % | 12 % | 8 % | (11 %) | 2 % | (5 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | 3 % | 3 % | 2 % | 3 % | 3 % |
Source: Company filings or news article
Related Content
Founded in 1993 by Zhao Buchang and his son Zhao Tao, Shandong Buchang Pharmaceuticals Co., Ltd. is a publicly traded company engaged in the research, development, production, and sale of traditional Chinese patent medicines. The company's genesis traces back to Zhao Buchang, a cardiovascular disease expert, and Zhao Tao's successful medical practice in Singapore, which provided the initial capital for the venture. The entire family, including Zhao Buchang's wife, two sons, and two daughters, were involved in the company's early stages. Based in Heze, Shandong, the company went public on the Shanghai Stock Exchange in November 2016.
Buchang Pharmaceuticals operates primarily in the traditional Chinese medicine (TCM) sector, with a strategic focus on treating major and chronic diseases. Its business model centers on the development and sale of patented TCM products, targeting hospitals, pharmacies, and healthcare professionals as its main clients. Revenue is generated through the sale of these pharmaceutical products, as well as through licensing agreements. The company has a significant marketing and sales network that covers various regions across China.
The company's core offerings are in the cardio-cerebrovascular field, built upon founder Zhao Buchang's "Naoxintongzhi" (brain and heart co-treatment) theory. Key products include the Naoxintong Capsule, Wenxin Granules, and Danhong Injection, which address conditions like stroke, arrhythmia, and coronary heart disease. Beyond its main focus, the company's portfolio extends to other areas such as gynecology, diabetes, oncology, and respiratory diseases. Buchang has production bases in Shandong, Shaanxi, and Hebei and has stated a strategic goal to transition from being marketing-driven to technology-driven, expanding into biopharmaceuticals, medical devices, and internet-based medicine.
Keywords: Traditional Chinese Medicine, cardio-cerebrovascular drugs, patent medicines, pharmaceutical manufacturing, Naoxintong Capsule, Wenxin Granules, Danhong Injection, gynecology medicine, oncology TCM, diabetes TCM, pharmaceutical sales, Heze, Zhao Buchang, Zhao Tao, Shanghai Stock Exchange, brain-heart co-treatment, Chinese patent medicine, pharmaceutical R&D, healthcare industry China
